CN104603152A - 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 - Google Patents

针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 Download PDF

Info

Publication number
CN104603152A
CN104603152A CN201380043349.7A CN201380043349A CN104603152A CN 104603152 A CN104603152 A CN 104603152A CN 201380043349 A CN201380043349 A CN 201380043349A CN 104603152 A CN104603152 A CN 104603152A
Authority
CN
China
Prior art keywords
ifn
type
patient
disorder
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380043349.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·希格斯
Y·姚
B·王
L·罗斯科斯
L·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104603152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN201810164604.8A priority Critical patent/CN108310375A/zh
Priority to CN202010333445.7A priority patent/CN111494624A/zh
Publication of CN104603152A publication Critical patent/CN104603152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pure & Applied Mathematics (AREA)
CN201380043349.7A 2012-06-13 2013-06-12 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 Pending CN104603152A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810164604.8A CN108310375A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
CN202010333445.7A CN111494624A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202010333445.7A Division CN111494624A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
CN201810164604.8A Division CN108310375A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案

Publications (1)

Publication Number Publication Date
CN104603152A true CN104603152A (zh) 2015-05-06

Family

ID=49758685

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380043349.7A Pending CN104603152A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
CN201810164604.8A Pending CN108310375A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
CN202010333445.7A Pending CN111494624A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810164604.8A Pending CN108310375A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
CN202010333445.7A Pending CN111494624A (zh) 2012-06-13 2013-06-12 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案

Country Status (9)

Country Link
US (1) US9493570B2 (https=)
EP (1) EP2861621A4 (https=)
JP (5) JP2015526391A (https=)
KR (3) KR102320059B1 (https=)
CN (3) CN104603152A (https=)
AU (3) AU2013274389A1 (https=)
CA (1) CA2876636C (https=)
HK (1) HK1209758A1 (https=)
WO (1) WO2013188494A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023976A1 (zh) * 2016-08-05 2018-02-08 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
CN108699608A (zh) * 2015-10-09 2018-10-23 基因前沿公司 用于预测和诊断人巨细胞病毒(hCMV)先天性传播的方法和试剂盒
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
WO2018172957A1 (en) 2017-03-21 2018-09-27 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
US11139051B2 (en) * 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
JP2022512796A (ja) 2018-10-26 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド Ｉ型インターフェロンシグネチャー及び使用方法
CN115925950A (zh) * 2019-01-31 2023-04-07 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
CA3216395A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN120392997A (zh) * 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
US20110008365A1 (en) * 2007-11-05 2011-01-13 Anthony Coyle Methods of treating scleroderma
CN101952454A (zh) * 2008-02-08 2011-01-19 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101678116A (zh) 2006-05-11 2010-03-24 根特大学 通过唾液酸粘附素靶向巨噬细胞
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
US20110008365A1 (en) * 2007-11-05 2011-01-13 Anthony Coyle Methods of treating scleroderma
CN101952454A (zh) * 2008-02-08 2011-01-19 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699608A (zh) * 2015-10-09 2018-10-23 基因前沿公司 用于预测和诊断人巨细胞病毒(hCMV)先天性传播的方法和试剂盒
WO2018023976A1 (zh) * 2016-08-05 2018-02-08 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法

Also Published As

Publication number Publication date
JP2021167336A (ja) 2021-10-21
AU2018206851B2 (en) 2020-07-30
HK1209758A1 (en) 2016-04-08
JP7123225B2 (ja) 2022-08-22
KR102185237B1 (ko) 2020-12-02
KR102320059B1 (ko) 2021-11-01
JP2019112429A (ja) 2019-07-11
AU2020204613B2 (en) 2021-10-07
AU2013274389A1 (en) 2015-01-22
KR20200133395A (ko) 2020-11-27
KR20210130270A (ko) 2021-10-29
JP2018065845A (ja) 2018-04-26
CA2876636A1 (en) 2013-12-19
AU2020204613A1 (en) 2020-07-30
AU2018206851A1 (en) 2018-08-09
EP2861621A1 (en) 2015-04-22
KR20150035825A (ko) 2015-04-07
CN108310375A (zh) 2018-07-24
US20150158949A1 (en) 2015-06-11
AU2018206851C1 (en) 2021-11-25
CA2876636C (en) 2022-09-13
KR102185237B9 (ko) 2021-08-06
CN111494624A (zh) 2020-08-07
US9493570B2 (en) 2016-11-15
JP2021042208A (ja) 2021-03-18
JP2015526391A (ja) 2015-09-10
EP2861621A4 (en) 2016-01-20
WO2013188494A1 (en) 2013-12-19
JP6814238B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7123225B2 (ja) 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
US20170121771A1 (en) Interferon alpha-induced pharmacodynamic markers and uses thereof
EP3359688B1 (en) Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
JP2018535394A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
CA2836926A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
KR20250017228A (ko) 근위축성 측색경화증의 치료 방법
Curry et al. Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?
IL302006A (en) Methods for treating cancer with antibody-drug conjugates (ADC) that bind to proteins 191P4D12
IL301163A (en) Methods for treating cancer with antibody-drug conjugates (ADC) that bind to proteins 191P4D12
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
Canadian Rheumatology Association Canadian Rheumatology Association Annual Scientific Meeting RBC Convention Centre (and Virtually) Winnipeg, Manitoba, Canada February 28–March 2, 2024
JP7854984B2 (ja) 細胞局在シグネチャーおよび免疫療法
Zeineddine Long-term safety and efficacy of high efficacy disease-modifying therapies in multiple sclerosis patients
JP2023538955A (ja) 細胞局在シグネチャーおよび免疫療法
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190416

Address after: Swedish Sodertalje

Applicant after: AstraZeneca AB

Address before: American Maryland

Applicant before: Medimmune Vaccines Inc.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20150506

RJ01 Rejection of invention patent application after publication